![](https://www.lachmanconsultants.com/wp-content/uploads/2019/03/iStock-585602900.jpg)
Changes and Updates to the FDA’s Guidance on Non-Proprietary Naming of Biotech Products
On Thursday, March 7, the FDA published a draft supplementary guidance on non-proprietary naming of biological products <here>, which updates the January 2017 Final Guidance on Nonproprietary Naming of Biological Products <here>. Both of these guidance documents address the FDA’s requirement for including a four-letter nonsense suffix in the proper name for biological products. This […]